Skip to content

Medical-device intelligence

QOF: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents

FDA product code QOF: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
QOF
FDA device name
Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents
Device class
2
Regulation number
866.3981
Medical specialty
Microbiology
Review panel
MI

FDA definition

A device to detect and identify nucleic acid targets in respiratory specimens from microbial agents that cause the SARS-CoV-2 respiratory infection and other microbial agents when in a multi-target test is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 and other microbial agents when in a multi-target test in human clinical respiratory specimens from patients suspected of respiratory infection who are at risk for exposure or who may have been exposed to these agents. The device is intended to aid in the diagnosis of respiratory infection in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.
Explore microbiology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

38 clearance records and 9 recall records in the covered releases, across 19 source company names and 1 product codes. Dated history runs from Feb 1, 2023 to Oct 30, 2026.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202511
November 202500
December 202510
January 202600
February 202610
March 202610
April 202601
May 202600
June 202611
July 202600
August 202600
September 202630
October 202630

Product codes represented

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

47 matching records
Device / recordCompany in FDA recordSourceSource date
Xpert Xpress CoV-2/Flu/RSV plusK242071 · QOFCepheid510(k)Jan 10, 2025FDA decision date
Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select PanelK241806 · QOFLife Technologies Corporation510(k)Jan 8, 2025FDA decision date
DASH® SARS-CoV-2 & Flu A/B TestK241652 · QOFNuclein, LLC510(k)Dec 20, 2024FDA decision date
Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay, REF: PRD-07400Z-0694-2025 · QOFHologic, Inc.RecallDec 20, 2024FDA classification date
Panther Fusion SARS-CoV-2/Flu A/B/RSV assayK242465 · QOFHologic, Inc.510(k)Nov 15, 2024FDA decision date
QIAstat-Dx Respiratory Panel MiniK242353 · QOFQIAGEN GmbH510(k)Oct 25, 2024FDA decision date
Panther Fusion SARS-CoV-2/Flu A/B/RSV AssayK241240 · QOFHologic, Inc.510(k)Jul 18, 2024FDA decision date
BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel MiniK241194 · QOFBiofire Diagnostics, LLC510(k)May 30, 2024FDA decision date
QIAstat-Dx® Respiratory Panel PlusK233100 · QOFQIAGEN GmbH510(k)May 10, 2024FDA decision date
BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) PanelK232954 · QOFBiofire Diagnostics, LLC510(k)Mar 26, 2024FDA decision date
NxTAG Respiratory Pathogen Panel v2 (NxTAG RPP v2)K231758 · QOFLuminex Molecular Diagnostics, Inc.510(k)Mar 11, 2024FDA decision date
LIAISON PLEX Respiratory Flex AssayK233410 · QOFLuminex Corporation510(k)Mar 1, 2024FDA decision date
The BIOFIRE Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BIOFIRE FILMARRAY 2.0 or BIOFIRE…Z-0704-2024 · QOFBioFire Diagnostics, LLCRecallJan 10, 2024FDA classification date
BioFire Respiratory Panel 2.1 (RP2.1), REF: 423742, For FILMARRAY systems, IVD, Rx OnlyZ-2439-2023 · QOFBioFire Diagnostics, LLCRecallAug 21, 2023FDA classification date
Xpert Xpress CoV-2/Flu/RSV plusK231481 · QOFCepheid®510(k)Aug 17, 2023FDA decision date
BD Respiratory Viral Panel for BD MAX™ System; BD Respiratory Viral Panel-SCV2 for BD MAX™ SystemK230956 · QOFBd Integrated Diagnostic Solutions /510(k)Jul 31, 2023FDA decision date
cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the cobas® Liat® SystemK223591 · QOFRoche Molecular Systems, Inc.510(k)Jul 27, 2023FDA decision date
Panther Fusion SARS-CoV-2/Flu A/B/RSV AssayK222736 · QOFHologic, Inc.510(k)May 16, 2023FDA decision date
BIOFIRE® SPOTFIRE® Respiratory (R) Panel MiniK230719 · QOFBiofire Diagnostics, LLC510(k)Apr 13, 2023FDA decision date
Simplexa COVID-19 & Flu A/B DirectK220963 · QOFDiasorin Molecular, LLC510(k)Mar 17, 2023FDA decision date
In Vitro Diagnostic (IVD) Panel BioFire Respiratory Panel 2.1 (RP2.1) - REF 423742Z-1252-2023 · QOFBioFire Diagnostics, LLCRecallMar 15, 2023FDA classification date
BIOFIRE SPOTFIRE Respiratory (R) PanelK213954 · QOFBiofire Diagnostics510(k)Feb 3, 2023FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗